Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection

Journal of Immunology

Volumn 163, Issue 7, 1999, Pages 3890-3897

  Ahuja, Seema S ^a,b,d   Reddick, Robert L ^a   Sato, Naoko ^a   Montalbo, Elleanor ^a   Kostecki, Vannessa ^a   Zhao, Weiguo ^a,b   Dolan, Matthew J ^c   Melby, Peter C ^a,b   Ahuja, Sunil K ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c WILFORD HALL MEDICAL CENTER   (United States)

^d Univ of Texas Health Science Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; GENE TRANSFER; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA DONOVANI; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; VISCERAL LEISHMANIASIS;

3T3 CELLS; ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, PROTOZOAN; DENDRITIC CELLS; GENETIC ENGINEERING; INJECTIONS, INTRAVENOUS; INTERLEUKIN-12; INTRACELLULAR FLUID; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTOZOAN VACCINES; TRANSFECTION; VACCINES, DNA;

EID: 0033214404     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Mahmoud, A. A. 1995. Tropical medicine: current problems and possible solutions. Infect. Dis. Clin. North Am. 9:265.
2. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
3. Steinman, R. M. 1996. Dendritic cells and immune-based therapies. Exp. Hematol. 24:859.
4. Romagnani, S. 1996. Understanding the role of Th1/Th2 cells in infection. Trends Microbiol. 4:470.
5. Lucey, D. R., M. Clerici, and G. M. Shearer. 1996. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin. Microbiol. Rev. 9:532.
6. Fresno, M., M. Kopf, and L. Rivas. 1997. Cytokines and infectious diseases. Immunol. Today 18:56.
7. Murphy, K. M. 1998. T lymphocyte differentiation in the periphery. Curr. Opin. Immunol. 10:226.
8. Trinchieri, G. 1998. Immunobiology of interleukin-12. Immunol. Res. 17:269.
9. Scott, P., and G. Trinchieri. 1997. IL-12 as an adjuvant for cell-mediated immunity. Semin. Immunol. 9:285.
10. Romani, L., P. Puccetti, and F. Bistoni. 1997. Interleukin-12 in infectious diseases. Clin. Microbiol. Rev. 10:611.
11. + effector T cells and susceptibility to infectious diseases. Adv. Exp. Med. Biol. 452:45.
12. Locksley, R. M., S. Pingel, D. Lacy, A. E. Wakil, M. Bix, and D. J. Fowell. 1999. Susceptibility to infectious diseases: Leishmania as a paradigm. J. Infect. Dis. 179(Suppl. 2):S305.
13. Holland, S. M., E. M. Eisenstein, D. B. Kuhns, M. L. Turner, T. A. Fleisher, W. Strober, and J. I. Gallin. 1994. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon γ: a preliminary report. N. Engl. J. Med. 330:1348.
14. Frucht, D. M., and S. M. Holland. 1996. Defective monocyte costimulation for IFN-γ production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J. Immunol. 157:411.
15. Newport, M. J., C. M. Huxley, S. Huston, C. M. Hawrylowicz, B. A. Oostra, R. Williamson, and M. Levin. 1996. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1941.
16. Jouanguy, E., F. Altare, S. Lamhamedi, P. Revy, J. F. Emile, M. Newport, M. Levin, S. Blanche, E. Seboun, A. Fischer, and J. L. Casanova. 1996. Interferon-γ-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335:1956.
17. Jouanguy, E., F. Altare, S. Lamhamedi-Cherradi, and J. L. Casanova. 1997. Infections in IFN-γ-receptor-1-deficient children. J. Interferon Cytokine Res. 17:583.
18. Pierre-Audigier, C., E. Jouanguy, S. Lamhamedi, F. Altare, J. Rauzier, V. Vincent, D. Canioni, J. F. Emile, A. Fischer, et al. 1997. Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon γ receptor deficiency. Clin. Infect. Dis. 24:982.
19. de Jong, R., F. Altare, I. A. Haagen, D. G. Elferink, T. Boer, P. J. van Breda Vriesman, P. J. Kabel, J. M. Draaisma, J. T. van Dissel, F. P. Kroon, et al. 1998. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280: 1435.
20. Altare, F., A. Durandy, D. Lammas, J. F. Emile, S. Lamhamedi, F. Le Deist, P. Drysdale, E. Jouanguy, R. Doffinger, F. Bernaudin, et al. 1998. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:1432.
21. Dorman, S. E., and S. M. Holland. 1998. Mutation in the signal-transducing chain of the interferon-γ receptor and susceptibility to mycobacterial infection. J. Clin. Invest. 101:2364.
22. Manickan, E., S. Kanangat, R. J. Rouse, Z. Yu, and B. T. Rouse. 1997. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J. Leukocyte Biol. 61:125.
23. Su, H., R. Messer, W. Whitmire, E. Fischer, J. C. Portis, and H. D. Caldwell. 1998. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J. Exp. Med. 188:809.
24. Ludewig, B., S. Ehl, U. Karrer, B. Odermatt, H. Hengartner, and R. M. Zinkernagel. 1998. Dendritic cells efficiently induce protective antiviral immunity. J. Virol. 72:3812.
25. Mbow, M. L., N. Zeidner, N. Panella, R. G. Titus, and J. Piesman. 1997. Borrelia burgdorferi-pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes. Infect. Immun. 65:3386.
26. Bourguin, I., M. Moser, D. Buzoni-Gatel, F. Tielemans, D. Bout, J. Urbain, and O. Leo. 1998. Murine dendritic cells pulsed in vitro with Toxoplasma gondii antigens induce protective immunity in vivo. Infect. Immun. 66:4867.
27. Francotte, M., and J. Urbain. 1985. Enhancement of antibody response by mouse dendritic cells pulsed with tobacco mosaic virus or with rabbit antiidiotypic antibodies raised against a private rabbit idiotype. Proc. Natl. Acad. Sci. USA 82:8149.
28. Schuler, G., and R. M. Steinman. 1997. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1183.
29. Song, W., H. L. Kong, H. Carpenter, H. Torii, R. Granstein, S. Rafii, M. A. Moore, and R. G. Crystal. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247.
30. Specht, J. M., G. Wang, M. T. Do, J. S. Lam, R. E. Royal, M. E. Reeves, S. A. Rosenberg, and P. Hwu. 1997. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1213.
31. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
32. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
33. Gilboa, E., S. K. Nair, and H. K. Lyerly. 1998. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46:82.
34. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52.
35. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328.
36. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4:525.
37. Taylor, A. P., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice. J. Exp. Med. 185:1231.
38. Melby, P. C., Y. Z. Yang, J. Cheng, and W. Zhao. 1998. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66:18.
39. Melby, P. C., and D. L. Sacks. 1989. Identification of antigens recognized by T cells in human leishmaniasis: analysis of T-cell clones by immunoblotting. Infect. Immun. 57:2971.
40. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
41. Lieschke, G. J., P. K. Rao, M. K. Gately, and R. C. Mulligan. 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat. Biotechnol. 15:35.
42. Ahuja, S. S., M. R. Brown, T. A. Fleisher, S. K. Ahuja, and H. L. Malech. 1996. Autocrine activation of hemopoietic progenitor-derived myelo-monocytic cells by IFN-γ gene transfer. J. Immunol. 156:4345.
43. Ahuja, S. S., S. Mummidi, H. L. Malech, and S. K. Ahuja. 1998. Human dendritic cell (DC)-based anti-infective therapy: engineering DCs to secrete functional IFN-γ and IL-12. J. Immunol. 161:868.
44. Buffet, P. A., A. Sulahian, Y. J. Garin, N. Nassar, and F. Derouin. 1995. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob. Agents Chemother. 39:2167.
45. Rodgers, M. R., S. J. Popper, and D. F. Wirth. 1990. Amplification of kinetoplast DNA as a tool in the detection and diagnosis of Leishmania. Exp. Parasitol. 71:267.
46. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322.
47. Eisenberger, C. L., and C. L. Jaffe. 1997. Vaccines against Leishmaniasis. In New Generation Vaccines. M.M. Levine, G.C. Woodrow, J.B. Kaper, and G.S. Cobon, eds. Marcel Dekker, New York, p. 1065.
48. Whalen, R. G. 1996. DNA vaccines for emerging infectious diseases: what if? Emerg. Infect. Dis. 2:168. .
49. Molling, K. 1997. Naked DNA for vaccine or therapy. J. Mol. Med. 75:242.
50. Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly. 1999. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59:56.
51. Morikawa, Y., K. Tohya, H. Ishida, N. Matsuura, and K. Kakudo. 1995. Different migration patterns of antigen-presenting cells correlate with Th1/Th2-type responses in mice. Immunology 85:575.
52. Kuribayashi, K., M. Tsukiyama, and T. Takenaka. 1997. Secretion patterns of Th1-and Th2-type cytokines in immune deviation caused by dendritic cells. Int. Arch. Allergy Immunol. 114:30.
53. Gilboa, E. 1996. Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol. 23:101.
54. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409.
55. Shimizu, Y., L. G. Guidotti, P. Fowler, and F. V. Chisari. 1998. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol. 161:4520.